JP2022532490A5 - - Google Patents
Info
- Publication number
- JP2022532490A5 JP2022532490A5 JP2021563296A JP2021563296A JP2022532490A5 JP 2022532490 A5 JP2022532490 A5 JP 2022532490A5 JP 2021563296 A JP2021563296 A JP 2021563296A JP 2021563296 A JP2021563296 A JP 2021563296A JP 2022532490 A5 JP2022532490 A5 JP 2022532490A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- amino acid
- acid sequence
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025015378A JP2025065211A (ja) | 2019-05-13 | 2025-01-31 | 癌の治療における有効性の増強のためのｐｄ－１阻害剤とｌａｇ－３阻害剤の組み合わせ |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962847068P | 2019-05-13 | 2019-05-13 | |
| US62/847,068 | 2019-05-13 | ||
| PCT/US2020/032515 WO2020232019A1 (en) | 2019-05-13 | 2020-05-12 | Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025015378A Division JP2025065211A (ja) | 2019-05-13 | 2025-01-31 | 癌の治療における有効性の増強のためのｐｄ－１阻害剤とｌａｇ－３阻害剤の組み合わせ |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022532490A JP2022532490A (ja) | 2022-07-15 |
| JP2022532490A5 true JP2022532490A5 (https=) | 2025-03-31 |
Family
ID=71069936
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021563296A Pending JP2022532490A (ja) | 2019-05-13 | 2020-05-12 | 癌の治療における有効性の増強のためのｐｄ－１阻害剤とｌａｇ－３阻害剤の組み合わせ |
| JP2025015378A Pending JP2025065211A (ja) | 2019-05-13 | 2025-01-31 | 癌の治療における有効性の増強のためのｐｄ－１阻害剤とｌａｇ－３阻害剤の組み合わせ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025015378A Pending JP2025065211A (ja) | 2019-05-13 | 2025-01-31 | 癌の治療における有効性の増強のためのｐｄ－１阻害剤とｌａｇ－３阻害剤の組み合わせ |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20220249659A1 (https=) |
| EP (1) | EP3969040A1 (https=) |
| JP (2) | JP2022532490A (https=) |
| KR (1) | KR20220007593A (https=) |
| CN (2) | CN120939219A (https=) |
| AU (1) | AU2020276242B2 (https=) |
| BR (1) | BR112021021713A2 (https=) |
| CA (1) | CA3136568A1 (https=) |
| CL (1) | CL2021002966A1 (https=) |
| EA (1) | EA202192528A1 (https=) |
| IL (1) | IL287728A (https=) |
| MA (1) | MA55965A (https=) |
| MX (1) | MX2021013815A (https=) |
| PH (1) | PH12021552675A1 (https=) |
| SG (1) | SG11202111262XA (https=) |
| WO (1) | WO2020232019A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI756187B (zh) * | 2015-10-09 | 2022-03-01 | 美商再生元醫藥公司 | 抗ｌａｇ３抗體及其用途 |
| AU2020380288B2 (en) * | 2019-11-04 | 2024-02-01 | Inovio Pharmaceuticals, Inc. | Combination therapy to treat brain cancer |
| EP4297782A1 (en) * | 2021-02-23 | 2024-01-03 | Regeneron Pharmaceuticals, Inc. | Methods of treating lung cancer by administering a pd-1 inhibitor |
| AU2022317820A1 (en) * | 2021-07-28 | 2023-12-14 | F. Hoffmann-La Roche Ag | Methods and compositions for treating cancer |
| IL310808A (en) | 2021-08-13 | 2024-04-01 | Inovio Pharmaceuticals Inc | Combination therapy to treat brain cancer |
| CN115960248A (zh) * | 2022-07-08 | 2023-04-14 | 盛禾(中国)生物制药有限公司 | 一种二聚体融合蛋白及其应用 |
| CN115887669A (zh) * | 2022-12-19 | 2023-04-04 | 国纳之星(上海)纳米科技发展有限公司 | 一种治疗癌症的药物组合物 |
| CN115869399B (zh) * | 2022-12-28 | 2024-01-12 | 广州誉衡生物科技有限公司 | 一种药物组合物和药物制剂及其在治疗非小细胞肺癌中的应用 |
| CN115845052B (zh) * | 2022-12-28 | 2023-12-29 | 广州誉衡生物科技有限公司 | 一种药物组合物和药物制剂及其在治疗结肠癌中的应用 |
| EP4680342A1 (en) * | 2023-03-13 | 2026-01-21 | Regeneron Pharmaceuticals, Inc. | Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating melanoma |
| AU2024379466A1 (en) * | 2023-11-15 | 2026-04-23 | Regeneron Pharmaceuticals, Inc. | Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating lung cancer |
| WO2025117889A2 (en) * | 2023-11-30 | 2025-06-05 | Regeneron Pharmaceuticals, Inc. | Methods of treating cancer by administering a combination therapy including a neoadjuvant pd-1 inhibitor |
| CN119607196A (zh) * | 2023-12-13 | 2025-03-14 | 正大天晴药业集团股份有限公司 | 抗lag-3抗体与抗pd-1抗体的应用 |
| WO2025237275A1 (zh) * | 2024-05-13 | 2025-11-20 | 南京维立志博生物科技股份有限公司 | 用于治疗肿瘤的抗lag-3抗体或其抗原结合部分 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5976877A (en) | 1990-01-08 | 1999-11-02 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Proteins produced by human lymphocytes DNA sequence encoding these proteins and their pharmaceutical and biological uses |
| FR2656800B1 (fr) | 1990-01-08 | 1992-05-15 | Roussy Inst Gustave | Nouvelles proteines produits par les lymphocytes humains, sequence d'adn codant pour ces proteines et applications pharmaceutiques et biologiques. |
| US5932448A (en) | 1991-11-29 | 1999-08-03 | Protein Design Labs., Inc. | Bispecific antibody heterodimers |
| US6129914A (en) | 1992-03-27 | 2000-10-10 | Protein Design Labs, Inc. | Bispecific antibody effective to treat B-cell lymphoma and cell line |
| CA2189657C (fr) | 1994-05-06 | 2002-03-12 | Florence Faure | Fractions polypeptidiques solubles de la proteine lag-3; procede de production; composition therapeutique; anticorps anti-idiotype |
| US5532210A (en) | 1994-06-08 | 1996-07-02 | E. I. Du Pont De Nemours And Company | High temperature superconductor dielectric slow wave structures for accelerators and traveling wave tubes |
| US6197524B1 (en) | 1995-07-21 | 2001-03-06 | Institute National De La Sante Et De La Recherche Medicale | Methods for detecting, identifying, isolating, and selectively labelling and targeting TH1 lymphocyte by means of the LAG-3 protein |
| EP0900841A1 (en) | 1997-06-18 | 1999-03-10 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | LAG-3 splice variants |
| HK1044159A1 (zh) | 1998-12-01 | 2002-10-11 | 蛋白质设计实验室股份有限公司 | 抗γ-干扰素的人化抗体 |
| US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| PL354286A1 (en) | 1999-08-23 | 2003-12-29 | Dana-Farber Cancer Institutedana-Farber Cancer Institute | Pd-1, a receptor for b7-4, and uses therefor |
| CN101899114A (zh) | 2002-12-23 | 2010-12-01 | 惠氏公司 | 抗pd-1抗体及其用途 |
| PL1897548T5 (pl) | 2003-02-28 | 2025-03-17 | The Johns Hopkins University | Regulacja komórek T |
| ES2463476T3 (es) | 2004-10-19 | 2014-05-28 | Regeneron Pharmaceuticals, Inc. | Método para generar un ratón homocigótico para una modificación genética |
| DK2439273T3 (da) | 2005-05-09 | 2019-06-03 | Ono Pharmaceutical Co | Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika |
| US9244059B2 (en) | 2007-04-30 | 2016-01-26 | Immutep Parc Club Orsay | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| BR122017025062B8 (pt) | 2007-06-18 | 2021-07-27 | Merck Sharp & Dohme | anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento |
| CN101970499B (zh) | 2008-02-11 | 2014-12-31 | 治疗科技公司 | 用于肿瘤治疗的单克隆抗体 |
| EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| AU2009288730B2 (en) | 2008-08-25 | 2013-06-20 | Amplimmune, Inc. | Compositions of PD-1 antagonists and methods of use |
| WO2011066342A2 (en) | 2009-11-24 | 2011-06-03 | Amplimmune, Inc. | Simultaneous inhibition of pd-l1/pd-l2 |
| JP6072771B2 (ja) | 2011-04-20 | 2017-02-01 | メディミューン，エルエルシー | Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子 |
| CA2840018C (en) | 2011-07-24 | 2019-07-16 | Curetech Ltd. | Variants of humanized immunomodulatory monoclonal antibodies |
| UY34887A (es) | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos |
| US10344088B2 (en) | 2013-03-15 | 2019-07-09 | Glaxosmithkline Intellectual Property Development Limited | Antigen binding proteins |
| JP6595458B2 (ja) * | 2013-09-20 | 2019-10-23 | ブリストル−マイヤーズ スクイブ カンパニー | 腫瘍を処置するための抗ｌａｇ−３抗体と抗ｐｄ−１抗体との組合せ |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| ES2791950T3 (es) | 2015-02-03 | 2020-11-06 | Ventana Med Syst Inc | Ensayo histoquímico para evaluar la expresión del ligando de muerte programada 1 (PD-L1) |
| US20180155429A1 (en) | 2015-05-28 | 2018-06-07 | Bristol-Myers Squibb Company | Treatment of pd-l1 positive lung cancer using an anti-pd-1 antibody |
| CN117510633A (zh) | 2015-09-02 | 2024-02-06 | 伊缪泰普有限公司 | 抗lag-3抗体 |
| TWI756187B (zh) * | 2015-10-09 | 2022-03-01 | 美商再生元醫藥公司 | 抗ｌａｇ３抗體及其用途 |
| TWI910495B (zh) * | 2016-05-13 | 2026-01-01 | 美商再生元醫藥公司 | 藉由投予pd-1抑制劑治療皮膚癌之方法 |
| RS61510B1 (sr) * | 2016-05-18 | 2021-03-31 | Boehringer Ingelheim Int | Anti pd-1 i anti-lag3 antitela za lečenje kancera |
| JP7066696B2 (ja) | 2016-10-11 | 2022-05-13 | アジェナス インコーポレイテッド | 抗ｌａｇ－３抗体及びその使用方法 |
| PH12019500668B1 (en) | 2016-10-13 | 2023-12-06 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | Anti-lag-3 antibodies and compositions |
| EP4649966A3 (en) | 2016-12-01 | 2026-02-18 | Regeneron Pharmaceuticals, Inc. | Radiolabeled anti-pd-l1 antibodies for immuno-pet imaging |
| EA201991673A1 (ru) | 2017-02-10 | 2020-01-17 | Регенерон Фармасьютикалз, Инк. | Меченные радиоактивным изотопом антитела к lag3 для иммуно-пэт-визуализации |
| UA129904C2 (uk) * | 2017-04-05 | 2025-09-10 | Ле Лаборатуар Сервьє | Комбінація антитіла до tim-3 й антитіла до pd-1 для лікування раку |
-
2020
- 2020-05-12 EP EP20731629.0A patent/EP3969040A1/en active Pending
- 2020-05-12 CN CN202511166496.4A patent/CN120939219A/zh active Pending
- 2020-05-12 PH PH1/2021/552675A patent/PH12021552675A1/en unknown
- 2020-05-12 WO PCT/US2020/032515 patent/WO2020232019A1/en not_active Ceased
- 2020-05-12 CA CA3136568A patent/CA3136568A1/en active Pending
- 2020-05-12 MX MX2021013815A patent/MX2021013815A/es unknown
- 2020-05-12 SG SG11202111262XA patent/SG11202111262XA/en unknown
- 2020-05-12 KR KR1020217034542A patent/KR20220007593A/ko active Pending
- 2020-05-12 CN CN202080035740.2A patent/CN113825527A/zh active Pending
- 2020-05-12 BR BR112021021713A patent/BR112021021713A2/pt unknown
- 2020-05-12 JP JP2021563296A patent/JP2022532490A/ja active Pending
- 2020-05-12 US US17/611,073 patent/US20220249659A1/en active Pending
- 2020-05-12 EA EA202192528A patent/EA202192528A1/ru unknown
- 2020-05-12 MA MA055965A patent/MA55965A/fr unknown
- 2020-05-12 AU AU2020276242A patent/AU2020276242B2/en active Active
-
2021
- 2021-10-31 IL IL287728A patent/IL287728A/en unknown
- 2021-11-10 CL CL2021002966A patent/CL2021002966A1/es unknown
-
2025
- 2025-01-31 JP JP2025015378A patent/JP2025065211A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022532490A5 (https=) | ||
| JP2022050618A5 (https=) | ||
| TWI786044B (zh) | 藉由投予ｐｄ-１抑制劑治療皮膚癌之方法 | |
| JP7126941B2 (ja) | がんを治療するための抗ｐｄ－１抗体と二重特異性抗ｃｄ２０／抗ｃｄ３抗体の組合せ | |
| AU2020276242B2 (en) | Combination of PD-1 inhibitors and LAG-3 inhibitors for enhanced efficacy in treating cancer | |
| JP2019515008A5 (https=) | ||
| CN108602889A (zh) | 医治急性成淋巴细胞性白血病的双特异性抗cd20/抗cd3抗体 | |
| IL321717A (en) | Anti-PD-1 antibodies for the treatment of lung cancer | |
| JP2020508317A5 (https=) | ||
| JP2021528423A5 (https=) | ||
| CA3129963A1 (en) | Il-4/il-13 pathway inhibitors for enhanced efficacy in treating cancer | |
| TW202320827A (zh) | 用於治療癌症之檢查點抑制劑和溶瘤病毒的組合 | |
| TWI899236B (zh) | 通過投予pd-1抑制劑治療子宮頸癌的方法 | |
| NZ781933B2 (en) | Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating cancer | |
| KR102956075B1 (ko) | 암을 치료하기 위한 항-pd-1 항체와 이특이적 항-cd20/항-cd3 항체의 조합 | |
| WO2025106736A2 (en) | Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating lung cancer | |
| RU2021128914A (ru) | Ингибиторы пути il-4/il-13 для повышенной эффективности при лечении злокачественных новообразований | |
| NZ748192B2 (en) | Methods of treating skin cancer by administering a pd-1 inhibitor |